Based on these figures and current medical practices in the United States, 1 potential strategy (strategy #1) could involve referring all women with either a family history of breast cancer, a pathogenic variant in BRCA1, BRCA2, and PALB2, or a pathogenic variant in ATM and CHEK2 coupled with a high PRS to a high-risk breast cancer clinic (Supplemental Figure 5A, Supplemental Table 11). This evidence concerns the gene CHEK2 and breast carcinoma.